2025
Forecasting optimal treatments in relapsed/refractory mature T‐ and NK‐cell lymphomas: A global PETAL Consortium study
Sorial M, Han J, Koh M, Boussi L, Li S, Duan R, Lu J, Lei M, MacVicar C, Freydman J, Malespini J, Aniagboso K, McCabe S, Peng L, Singh S, Iwasaki M, Eche‐Ugwu I, Gabler J, Turizo M, Garg A, Disciullo A, Chopra K, Ford J, Lenart A, Nwodo E, Barnes J, Koh M, Miranda E, Chiattone C, Stuver R, Merrill M, Jacobsen E, Manni M, Civallero M, Skrypets T, Lymboussaki A, Federico M, Kim Y, Kim J, Cho J, Eipe T, Shet T, Epari S, Shetty A, Saha S, Jain H, Sengar M, Van Der Weyden C, Prince H, Hamouche R, Muradashvili T, Foss F, Gentilini M, Casadei B, Zinzani P, Okatani T, Yoshida N, Yoon S, Kim W, Panchoo G, Mohamed Z, Verburgh E, Alturas J, Al‐Mansour M, Cabrera M, Ku A, Bhagat G, Ma H, Sawas A, Kariya K, Bhanushali F, Meharwal A, Mistry D, Kosovsky M, Yeterian M, O'Connor O, Marchi E, Shen C, Shah D, Jain S. Forecasting optimal treatments in relapsed/refractory mature T‐ and NK‐cell lymphomas: A global PETAL Consortium study. British Journal Of Haematology 2025, 206: 1664-1677. PMID: 40310502, PMCID: PMC12167149, DOI: 10.1111/bjh.20063.Peer-Reviewed Original ResearchConceptsT-cell lymphomaCytotoxic chemotherapySmall molecule inhibitorsEpigenetic modifiersAngioimmunoblastic T-cell lymphomaPrimary refractory diseaseNK-cell lymphomasHigh-risk groupTransplant consolidationOverall survivalRefractory diseaseNK cellsPrognostic indexT cellsIdeal therapyMature TOptimal treatmentLymphomaGlobal cohortTreatment sequenceMolecule inhibitorsPatientsThird lineConsortium studyTreatment
2021
HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy
Arora S, Catania R, Borhani A, Horvat N, Fowler K, Harmath C. HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy. Abdominal Radiology 2021, 46: 3686-3697. PMID: 34195886, DOI: 10.1007/s00261-021-03192-8.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaTumor biologyHCC tumor biologyRare responsesTreatment hepatocellular carcinomaPost-treatment responsePrognostic featuresAbscopal effectAdverse outcomesCancer deathIdeal therapyEffective therapyImaging featuresDisease evolveIndividual patientsLiver cancerMore therapiesTumor behaviorTreatment planParticular tumorTherapyClinical useTreatment planningPatientsTumors
2005
Contrasting Challenges of Insulin Pump Therapy in a Toddler and Adolescent With Type 1 Diabetes
Doyle Boland EA, Steffen AT, Tamborlane WV. Contrasting Challenges of Insulin Pump Therapy in a Toddler and Adolescent With Type 1 Diabetes. The Science Of Diabetes Self-Management And Care 2005, 31: 584-590. PMID: 16100334, DOI: 10.1177/0145721705278888.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionType 1 diabetesGlycemic controlCSII therapyHypoglycemic episodesInsulin bolus dosesHemoglobin A1c levelsPediatric diabetes clinicSevere hypoglycemic episodesInsulin pump therapySubcutaneous insulin infusionYears of ageAge 13 yearsA1c levelsCatheter siteDiabetes clinicBolus dosesPump therapyDaily injectionsIdeal therapyInsulin infusionInsulin injectionsPostprandial hyperglycemiaFood intakePump use
1996
Pulmonary Arteriovenous Malformations: Diagnosis and Transcatheter Embolotherapy
White R, Pollak J, Wirth J. Pulmonary Arteriovenous Malformations: Diagnosis and Transcatheter Embolotherapy. Journal Of Vascular And Interventional Radiology 1996, 7: 787-804. PMID: 8951745, DOI: 10.1016/s1051-0443(96)70851-5.Peer-Reviewed Educational MaterialsConceptsTranscatheter embolotherapyPulmonary malformationsUse of embolotherapyLong-term followOptions of treatmentLonger procedure timeRecent long-term studiesPollak et alParadoxical embolizationDefinitive treatmentInitial treatmentLate recurrenceRecurrence rateSurgical interventionIdeal therapyDetachable balloonsSegmental arteriesPrimary treatmentAnatomic situationDurable resultsProcedure timePrimary modalityLarge seriesPatientsEmbolotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply